More than 11,000 Americans are still actively litigating claims against the makers of Nexium, Prilosec, and Prevacid — and thousands more may not yet know they qualify. The proton pump inhibitor lawsuit consolidated in federal court has become one of the most significant pharmaceutical mass torts in the country, with total settlements now exceeding half a billion dollars and a major defendant still without a global resolution. If you or someone you love took a PPI for six months or more and later developed kidney disease, what happens next in this litigation matters directly to you.
What Is MDL 2789 and Where Does It Stand in 2026?
MDL 2789, formally titled In re Proton-Pump Inhibitor Products Liability Litigation, is consolidated before Judge Claire C. Cecchi in the U.S. District Court for the District of New Jersey. The Judicial Panel on Multidistrict Litigation centralized the litigation in August 2017, beginning with 161 initial cases. What started as a relatively contained docket has grown into one of the largest active pharmaceutical MDLs in the United States.
As of July 2026, the docket reflects 18,706 total U.S. filings with 11,321 cases still active, according to JPML statistics. That makes MDL 2789 one of the largest active pharmaceutical MDLs in the country. The defendants named across these cases include AstraZeneca (manufacturer of Nexium and Prilosec), Takeda Pharmaceuticals (Prevacid), Pfizer and Wyeth (Protonix), and Procter & Gamble. Every major brand of prescription and over-the-counter proton pump inhibitor is represented in this litigation.
The scale of this proton pump inhibitor lawsuit reflects just how widely these medications were used. FDA data shows that approximately 21 million patients filled PPI prescriptions at U.S. outpatient retail pharmacies in a single year, making PPIs the second-largest drug class by U.S. sales. The volume of exposure — and the severity of the injuries alleged — explains why this MDL has drawn so many claimants over nearly a decade of litigation. Notably, 653 cases were resolved in 2025 alone as the settlement and claims-administration process continues to advance.
AstraZeneca’s $425M Settlement and the Current Payout Phase
The most significant financial development in the proton pump inhibitor lawsuit to date is AstraZeneca’s October 2023 settlement covering Nexium and Prilosec claims. Announced just days before a scheduled October 10, 2023 bellwether trial was set to begin, the deal was valued at $425 million and covered approximately 11,000 cases. As of mid-2026, that settlement is firmly in the distribution phase, with qualifying claimants actively receiving compensation and some expected to receive payments before year-end 2026.
Individual settlement payouts in the AstraZeneca resolution vary considerably depending on the severity of a claimant’s kidney injury. Estimates range from approximately $20,000 for less severe diagnoses such as acute interstitial nephritis up to $150,000 or more for claimants who developed chronic kidney disease or end-stage renal disease requiring dialysis or transplant. The claims administrator is evaluating each case individually based on medical documentation, duration of PPI use, and other qualifying factors.
The timing of AstraZeneca’s settlement — on the eve of trial — underscores the litigation pressure that bellwether cases create in mass tort MDLs. When a defendant settles rather than proceed to jury verdict, it signals that the underlying liability evidence presents real risk. Total settlements across all defendants in this MDL now exceed half a billion dollars. For claimants whose cases were included in the AstraZeneca resolution, the focus has shifted from litigation strategy to navigating the claims-administration process and ensuring all required documentation has been submitted to secure timely payment.
Takeda Still Unresolved: What Prevacid and Protonix Claimants Face
While AstraZeneca’s settlement has brought resolution to thousands of Nexium and Prilosec claimants, the picture is sharply different for those who primarily used Prevacid or Protonix. As of 2026, Takeda Pharmaceuticals and Procter & Gamble have not agreed to a global settlement, leaving the outstanding claims against these non-AstraZeneca defendants unresolved. This means that for a significant portion of the 11,321 still-active cases in MDL 2789, the litigation path forward remains uncertain and potentially lengthy.
Plaintiffs whose claims center on Prevacid use face the same fundamental challenge that preceded AstraZeneca’s settlement: building enough bellwether trial pressure to compel a global resolution. The fact that AstraZeneca settled just before trial is instructive — it suggests that defendants in this MDL take the prospect of jury verdicts seriously. Attorneys representing Prevacid and Protonix claimants are continuing to pursue discovery and pre-trial proceedings in anticipation of future bellwether scheduling.
For claimants who used multiple PPI brands, the situation is more complex. If you took both Nexium and Prevacid, for example, your claim may have a component that falls under the AstraZeneca settlement and a separate component that remains in active litigation against Takeda. An experienced mass tort attorney can help you understand how your specific drug history affects which defendants are potentially liable and what your realistic litigation timeline looks like going into 2026 and beyond.
The Science: What Research Says About PPIs and Kidney Disease
The legal claims in MDL 2789 are grounded in a body of peer-reviewed research linking long-term PPI use to kidney disease. The foundational studies emerged between 2015 and 2017 and have been replicated and expanded in the years since. A 2016 study published in the Journal of the American Society of Nephrology found that PPI users had a 28 percent higher risk of developing chronic kidney disease compared to non-users, with twice-daily users facing a 46 percent higher risk. A separate 2017 study published in PLOS ONE followed more than 125,000 new PPI users and found a significantly elevated risk of kidney failure.
The biological mechanism most frequently cited in the litigation is acute interstitial nephritis, an inflammatory condition affecting the kidney’s tubules and surrounding tissue. Unlike many drug injuries that manifest quickly, AIN can develop gradually and is often diagnosed only after significant kidney function has already been lost. Research suggests that repeated or prolonged PPI exposure can trigger immune-mediated inflammation in kidney tissue, leading to scarring and, in severe cases, progression to chronic kidney disease or end-stage renal disease.
Critically, the plaintiffs allege that the manufacturers knew or should have known about these risks and failed to adequately warn prescribing physicians and patients. Internal company documents produced during discovery have been central to establishing what each defendant knew about kidney-related adverse events and when they knew it. The fact that AstraZeneca chose to settle rather than defend its conduct before a jury is widely viewed as meaningful in evaluating the overall strength of the scientific and legal case.
MDL 2789 by the Numbers: Key Statistics at a Glance
- 18,706 — Total cases filed in MDL 2789 as of July 2026
- 11,321 — Active cases still pending in the MDL as of July 2026
- 653 — Cases resolved during 2025 as settlement and claims administration advanced
- $425 million — Value of AstraZeneca’s Nexium/Prilosec settlement, now in the distribution phase
- $500 million+ — Estimated total settlements across all defendants in MDL 2789
- $20,000–$150,000+ — Estimated individual payout range depending on severity of kidney injury
- August 2017 — Date MDL 2789 was centralized by the Judicial Panel on Multidistrict Litigation
- 21 million — Approximate number of U.S. patients who filled PPI prescriptions in a single year, per FDA data
- 0 — Global settlements reached by Takeda Pharmaceuticals or Procter & Gamble as of mid-2026
Who Qualifies for the Proton Pump Inhibitor Lawsuit in 2026?
Eligibility for the proton pump inhibitor lawsuit generally turns on two core questions: what drug did you take, and what injury did you develop? While each case is evaluated individually, attorneys handling PPI litigation in 2026 are typically looking for claimants who meet the following general criteria.
Drug use: You used a prescription or over-the-counter proton pump inhibitor for six months or longer. The drugs most commonly at issue include Nexium (esomeprazole), Prilosec (omeprazole), Prevacid (lansoprazole), Protonix (pantoprazole), Aciphex (rabeprazole), and Dexilant (dexlansoprazole). Generic versions of these drugs may also qualify depending on the manufacturer and the specific facts of your case.
Injury: You were diagnosed with one or more of the following kidney conditions: acute interstitial nephritis (AIN), chronic kidney disease (CKD), end-stage renal disease (ESRD), or acute kidney injury (AKI). Claimants with ESRD — particularly those who have required dialysis or kidney transplant — typically have the strongest cases and the highest potential compensation values under individual settlement formulas.
Timing: Your kidney diagnosis occurred during or after your period of PPI use. Cases where the diagnosis preceded PPI use or where there are clearly established alternative causes for the kidney disease may face additional scrutiny during the claims evaluation process.
Documentation: Medical records confirming both your PPI prescriptions (or OTC purchase history) and your kidney diagnosis are essential. Pharmacy records, prescription printouts, and nephrology or primary care records establishing the timeline of drug use and diagnosis form the evidentiary backbone of any individual claim.
If you are unsure whether your situation meets these criteria, the best step is a free case evaluation with a mass tort attorney who handles PPI litigation. Many firms work on contingency, meaning there is no cost to you unless your case results in a recovery.
What You Need to Do Right Now If You Used PPIs and Developed Kidney Disease
With AstraZeneca’s settlement in the distribution phase and the Takeda litigation continuing without a global resolution in sight, 2026 is a consequential year for PPI claimants at every stage. Here is what you should prioritize right now.
Gather your medical and pharmacy records. If you have not already done so, request complete records from every pharmacy you used during the period you took PPIs, as well as records from any nephrologist, primary care physician, or hospitalist who treated your kidney condition. These records are the foundation of your claim and can take weeks to obtain.
Do not assume AstraZeneca’s settlement covers you. The $425 million deal covered Nexium and Prilosec claims specifically. If you primarily used Prevacid, Protonix, or another non-AstraZeneca PPI, your claim may be part of the unresolved litigation against Takeda, Pfizer/Wyeth, or Procter & Gamble. Understanding which defendants are relevant to your case requires a fact-specific analysis of your drug history.
Be aware of statutes of limitations. Mass tort MDLs do not pause state-law statutes of limitations. Depending on where you live and when your injury was diagnosed or should have been discovered, your window to file may be limited. An attorney can evaluate whether your claim is still timely and, if necessary, take immediate steps to preserve your right to file.
Consult a mass tort attorney before acting alone. The claims-administration process for the AstraZeneca settlement and any future Takeda resolution involves complex legal documentation. Claimants who attempt to navigate these processes without legal representation frequently leave compensation on the table or make procedural errors that affect their recovery. Most PPI attorneys offer free consultations and handle cases on a contingency basis.
Act with urgency if you have ESRD. Claimants who developed end-stage renal disease — particularly those who have undergone dialysis or received a kidney transplant — have suffered the most serious injuries recognized in this litigation and typically qualify for the highest tier of compensation. If you or a family member is in this category, retaining counsel promptly is especially important as the litigation against remaining defendants continues to develop.
Frequently Asked Questions About the Proton Pump Inhibitor Lawsuit
What kidney diseases qualify for the proton pump inhibitor lawsuit?
The kidney conditions most commonly recognized in PPI litigation include acute interstitial nephritis (AIN), chronic kidney disease (CKD), end-stage renal disease (ESRD), and acute kidney injury (AKI). Among these, ESRD — particularly cases requiring dialysis or kidney transplant — is generally associated with the highest compensation values, with individual estimates ranging upward of $150,000 or more depending on the specific facts of the claim. AIN and earlier-stage CKD cases have also been compensated, with individual payouts estimated in the range of $20,000 to $150,000 depending on severity, duration of illness, and other factors evaluated during claims administration.
Did AstraZeneca’s $425M settlement resolve all PPI claims?
No. AstraZeneca’s $425 million settlement, which is now in the distribution phase in 2026, covered claims related specifically to Nexium and Prilosec. Takeda Pharmaceuticals (maker of Prevacid) and Procter & Gamble have not reached a global settlement as of mid-2026. Thousands of active cases remain pending in MDL 2789 against these and other defendants. If your PPI claims involve Prevacid, Protonix, or other non-AstraZeneca drugs, your litigation is ongoing and has not been resolved by AstraZeneca’s deal.
How long did I need to take a PPI to qualify for a lawsuit?
Most attorneys handling PPI litigation look for a minimum of six months of continuous or near-continuous PPI use. This threshold is grounded in the research suggesting that kidney injury risk increases with duration of exposure. Shorter periods of use may be evaluated on a case-by-case basis, particularly if the claimant developed acute interstitial nephritis, which can sometimes manifest with less prolonged exposure. The specific drug, dosage, and frequency of use are all factors considered during the initial case evaluation.
What is the legal theory behind PPI kidney disease claims?
PPI kidney disease claims are primarily based on product liability theories, including failure to warn, design defect, and negligence. The central allegation is that the manufacturers knew or should have known that long-term PPI use was associated with kidney injury risks — including acute interstitial nephritis and chronic kidney disease — and failed to adequately disclose those risks to prescribing physicians and patients. Plaintiffs argue that had they or their doctors been properly warned, they would have chosen alternative acid-reflux treatments or used PPIs for shorter durations, potentially avoiding the kidney injuries they developed.
Is it too late to file a proton pump inhibitor lawsuit claim in 2026?
Whether it is too late depends on the statute of limitations in your state and when your kidney injury was diagnosed or reasonably should have been discovered. Many states apply a discovery rule that starts the limitations clock from the date a plaintiff knew or should have known their injury was connected to PPI use — not necessarily the date of the kidney diagnosis itself. Because statutes of limitations vary significantly by state and fact pattern, the only reliable way to know whether your claim is still timely is to consult a mass tort attorney promptly. With Takeda and other defendants still unresolved as of mid-2026, new claims are still being evaluated, but delay carries real legal risk.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.